An RRx-001 Analogue With Potent Anti-NLRP3 Inflammasome Activity but Without High-Energy Nitro Functional Groups
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
An RRx-001 Analogue With Potent Anti-NLRP3 Inflammasome Activity but Without High-Energy Nitro Functional Groups
Authors
Keywords
-
Journal
Frontiers in Pharmacology
Volume 13, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2022-02-17
DOI
10.3389/fphar.2022.822833
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- NLRP3 inflammasome inhibitor INF39 attenuated NLRP3 assembly in macrophages
- (2021) Yuhua Shi et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- RRx-001 ameliorates inflammatory diseases by acting as a potent covalent NLRP3 inhibitor
- (2021) Yun Chen et al. Cellular & Molecular Immunology
- MCC950 directly targets the NLRP3 ATP-hydrolysis motif for inflammasome inhibition
- (2019) Rebecca C. Coll et al. Nature Chemical Biology
- NLRP3 inhibitors stoke anti-inflammatory ambitions
- (2019) Asher Mullard NATURE REVIEWS DRUG DISCOVERY
- Structural mechanism for NEK7-licensed activation of NLRP3 inflammasome
- (2019) Humayun Sharif et al. NATURE
- REPLATINUM Phase III randomized study: RRx-001 + platinum doublet versus platinum doublet in third-line small cell lung cancer
- (2019) Bryan Oronsky et al. Future Oncology
- One-Carbon Metabolism Supports S-Adenosylmethionine and Histone Methylation to Drive Inflammatory Macrophages
- (2019) Weiwei Yu et al. MOLECULAR CELL
- Development of small molecule inhibitors targeting NLRP3 inflammasome pathway for inflammatory diseases
- (2019) Xiangna Zhang et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Tranilast directly targets NLRP3 to treat inflammasome‐driven diseases
- (2018) Yi Huang et al. EMBO Molecular Medicine
- OLT1177, a β-sulfonyl nitrile compound, safe in humans, inhibits the NLRP3 inflammasome and reverses the metabolic cost of inflammation
- (2018) Carlo Marchetti et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Oridonin is a covalent NLRP3 inhibitor with strong anti-inflammasome activity
- (2018) Hongbin He et al. Nature Communications
- Overview of the IL-1 family in innate inflammation and acquired immunity
- (2017) Charles A. Dinarello IMMUNOLOGICAL REVIEWS
- Identification of a selective and direct NLRP3 inhibitor to treat inflammatory disorders
- (2017) Hua Jiang et al. JOURNAL OF EXPERIMENTAL MEDICINE
- CLICs-dependent chloride efflux is an essential and proximal upstream event for NLRP3 inflammasome activation
- (2017) Tiantian Tang et al. Nature Communications
- RRx-001: a systemically non-toxic M2-to-M1 macrophage stimulating and prosensitizing agent in Phase II clinical trials
- (2016) Bryan Oronsky et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- K + Efflux-Independent NLRP3 Inflammasome Activation by Small Molecules Targeting Mitochondria
- (2016) Christina J. Groß et al. IMMUNITY
- NEK7 is an essential mediator of NLRP3 activation downstream of potassium efflux
- (2016) Yuan He et al. NATURE
- Whole Brain Radiotherapy and RRx-001: Two Partial Responses in Radioresistant Melanoma Brain Metastases from a Phase I/II Clinical Trial
- (2016) Michelle M. Kim et al. Translational Oncology
- ASC filament formation serves as a signal amplification mechanism for inflammasomes
- (2016) Mathias S. Dick et al. Nature Communications
- Fenamate NSAIDs inhibit the NLRP3 inflammasome and protect against Alzheimer’s disease in rodent models
- (2016) Michael J. D. Daniels et al. Nature Communications
- Inflammasome-Independent Regulation of IL-1-Family Cytokines
- (2015) Mihai G. Netea et al. Annual Review of Immunology
- Epithelial IL-18 Equilibrium Controls Barrier Function in Colitis
- (2015) Roni Nowarski et al. CELL
- Safety and activity of RRx-001 in patients with advanced cancer: a first-in-human, open-label, dose-escalation phase 1 study
- (2015) Tony Reid et al. LANCET ONCOLOGY
- Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death
- (2015) Jianjin Shi et al. NATURE
- NLRP3 activation and mitosis are mutually exclusive events coordinated by NEK7, a new inflammasome component
- (2015) Hexin Shi et al. NATURE IMMUNOLOGY
- A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases
- (2015) Rebecca C Coll et al. NATURE MEDICINE
- Inflammasomes: mechanism of action, role in disease and therapeutics
- (2015) Haitao Guo et al. NATURE MEDICINE
- Mitochondria: diversity in the regulation of the NLRP3 inflammasome
- (2015) Prajwal Gurung et al. TRENDS IN MOLECULAR MEDICINE
- Mechanistic basis of Nek7 activation through Nek9 binding and induced dimerization
- (2015) Tamanna Haq et al. Nature Communications
- Unified Polymerization Mechanism for the Assembly of ASC-Dependent Inflammasomes
- (2014) Alvin Lu et al. CELL
- Innate immune sensing of bacterial modifications of Rho GTPases by the Pyrin inflammasome
- (2014) Hao Xu et al. NATURE
- K+ Efflux Is the Common Trigger of NLRP3 Inflammasome Activation by Bacterial Toxins and Particulate Matter
- (2013) Raúl Muñoz-Planillo et al. IMMUNITY
- Treating inflammation by blocking interleukin-1 in humans
- (2013) Charles A. Dinarello et al. SEMINARS IN IMMUNOLOGY
- Dinitroazetidines Are a Novel Class of Anticancer Agents and Hypoxia-Activated Radiation Sensitizers Developed from Highly Energetic Materials
- (2012) S. Ning et al. CANCER RESEARCH
- TLR Agonists Stimulate Nlrp3-Dependent IL-1 Production Independently of the Purinergic P2X7 Receptor in Dendritic Cells and In Vivo
- (2012) Y. He et al. JOURNAL OF IMMUNOLOGY
- NLRP3 is activated in Alzheimer’s disease and contributes to pathology in APP/PS1 mice
- (2012) Michael T. Heneka et al. NATURE
- A role for the NLRP3 inflammasome in metabolic diseases—did Warburg miss inflammation?
- (2012) Haitao Wen et al. NATURE IMMUNOLOGY
- Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases
- (2012) Charles A. Dinarello et al. NATURE REVIEWS DRUG DISCOVERY
- Development of a Safe and Efficient Two-Step Synthesis for Preparing 1-Bromoacetyl-3,3-dinitroazetidine, a Novel Clinical Anticancer Candidate
- (2012) Nicholas A. Straessler et al. ORGANIC PROCESS RESEARCH & DEVELOPMENT
- The Inflammasome NLRs in Immunity, Inflammation, and Associated Diseases
- (2011) Beckley K. Davis et al. Annual Review of Immunology
- IL-1 and TNF -initiated IL-6-STAT3 pathway is critical in mediating inflammatory cytokines and RANKL expression in inflammatory arthritis
- (2011) T. Mori et al. INTERNATIONAL IMMUNOLOGY
- Caspase-1-Processed Cytokines IL-1 and IL-18 Promote IL-17 Production by and CD4 T Cells That Mediate Autoimmunity
- (2011) S. J. Lalor et al. JOURNAL OF IMMUNOLOGY
- The Inflammasomes
- (2010) Kate Schroder et al. CELL
- Colitis induced in mice with dextran sulfate sodium (DSS) is mediated by the NLRP3 inflammasome
- (2010) C. Bauer et al. GUT
- NLRP3 Plays a Critical Role in the Development of Experimental Autoimmune Encephalomyelitis by Mediating Th1 and Th17 Responses
- (2010) D. Gris et al. JOURNAL OF IMMUNOLOGY
- A role for mitochondria in NLRP3 inflammasome activation
- (2010) Rongbin Zhou et al. NATURE
- NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals
- (2010) Peter Duewell et al. NATURE
- Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1β in type 2 diabetes
- (2010) Seth L Masters et al. NATURE IMMUNOLOGY
- Target identification using drug affinity responsive target stability (DARTS)
- (2009) B. Lomenick et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started